Is Lifecore Biomedical, Inc. overvalued or undervalued?

As of 2 January 2025, Lifecore Biomedical, Inc. has moved from a fair to risky valuation grade. The company is currently assessed as overvalued given its significant negative performance indicators. Key ratios include a Price to Book Value of 5.35, an EV to EBIT of -30.78, and an ROE of -89.08%.
In comparison to peers, Ocular Therapeutix, Inc. has a P/E of -6.7319 and an EV to EBITDA of -5.2132, while Vanda Pharmaceuticals, Inc. shows a P/E of -5.9803 with an EV to EBITDA of 1.1136. These comparisons highlight that Lifecore's valuation metrics are considerably worse than its peers, reinforcing the conclusion of overvaluation. Despite a recent 1-year stock return of 47.21%, the overall financial health and performance metrics suggest that the stock is not justified at its current price level.